Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein...

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Glycogen synthase kinase 3 beta (GSK-3beta) is implicated in central nervous system (CNS) disorders.
• Inhibiting GSK-3beta activity is a potential therapeutic strategy for neurodegenerative conditions.

Purpose of the Study:

• To synthesize and evaluate novel small molecules as inhibitors of GSK-3beta.
• To investigate the efficacy of these inhibitors in reducing Tau phosphorylation and protecting against neurotoxicity.

Main Methods:

• Kinase-screening assays to identify initial inhibitors.
• Synthesis of a series of 3-indolyl-4-indazolylmaleimides.
• Enzymatic and cell-based assays to assess GSK-3beta inhibition and Tau phosphorylation.
• Evaluation of neuroprotective effects against MPP+-induced neurotoxicity.

Main Results:

• Identified potent GSK-3beta inhibitors (maleimides 18 and 22) with Ki < 8 nM.
• Demonstrated that only potent inhibitors effectively reduced Tau phosphorylation at Ser 396/404.
• Showed that maleimides 18 and 22 protected neuronal cells against MPP+-induced neurotoxicity, potentially by decreasing alpha-Syn protein expression.

Conclusions:

• Novel 3-indolyl-4-indazolylmaleimides are potent GSK-3beta inhibitors.
• These compounds effectively inhibit Tau phosphorylation and offer neuroprotection.
• GSK-3beta inhibitors show promise for treating Parkinson's disease and other Tau-related neurodegenerative disorders.